Sir John Bell, GBE CH FRS, is a Canadian-British immunologist and geneticist who served as Regius Professor of Medicine at the University of Oxford from 2002 to 2024 – only the second Canadian to hold that position after Sir William Osler. He is a founding director of the Wellcome Trust Centre for Human Genetics, a former President of the UK Academy of Medical Sciences, and a UK Government Life Sciences Champion. Sir John has advised Prime Ministers and governments across the UK and Canada on biomedical strategy and is currently a Partner at Population Health Partners.

Dr. Robert Califf, MD, served as the 25th Commissioner of the U.S. Food and Drug Administration under both the Obama and Biden administrations (2016–2017; 2022–2025), making him the only person to lead the FDA twice. A nationally recognized cardiologist and clinical trialist, he is the founding director of the Duke Clinical Research Institute and one of the most cited authors in biomedical science, with over 1,300 peer-reviewed publications. Prior to his second FDA tenure, Dr. Califf served as head of medical strategy at Alphabet's Verily Life Sciences and Google Health. He is currently a Partner at Population Health Partners.

Dr. Gary Foster, PhD, is a clinical psychologist, obesity researcher, and behavior change expert who served as Chief Science Officer at Weight Watchers from 2013-2025. Before joining WW, he founded and directed the Center for Obesity Research and Education at Temple University, where he held the Laura Carnell Professorship in Medicine, Public Health, and Psychology. He has authored more than 250 scientific publications and three books on the etiology and treatment of obesity, and has received recognition from The Obesity Society, the American Psychological Association, and the Academy of Nutrition and Dietetics for his contributions to the field.

Dr. Melanie Jay, MD, MS, is a Professor of Medicine and Population Health at NYU Grossman School of Medicine and a board-certified obesity medicine specialist. She directs the NYU Langone Comprehensive Program on Obesity and leads the MOTIVATE Research Lab, which develops scalable, evidence-based interventions to improve obesity treatment in primary care – with a particular focus on underserved and veteran populations. Dr. Jay holds a K24 research career award from the NIH and sees patients at the New York Harbor Veterans Affairs Healthcare System. She has delivered a widely viewed TEDx talk on the future of obesity care.

Dr. Ian Neeland, MD, FAHA, FACC, is a preventive cardiologist with specialized expertise in obesity, diabetes, and cardiovascular disease. He serves as Director of Cardiovascular Prevention and Co-Director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at University Hospitals Harrington Heart & Vascular Institute, and as Associate Professor of Medicine at Case Western Reserve University School of Medicine. Dr. Neeland received his medical degree from Icahn School of Medicine at Mount Sinai and trained at Emory University and UT Southwestern. He co-authored the American Heart Association's 2021 Scientific Statement on Obesity and Cardiovascular Disease.

Dr. Robert Stoekenbroek, MD, PhD, is a physician-scientist with a background in preventive cardiology who has specific expertise in the treatment of lipid disorders and in cardiometabolic drug development. Trained at the University of Amsterdam, he started his career in clinical medicine and transitioned to the biopharmaceutical industry at The Medicines Company. He has led clinical development and portfolio strategy across major biopharmaceutical organizations including Novartis and Metsera, where he advanced next-generation GLP-1 receptor agonist programs for obesity and metabolic disease. Dr. Stoekenbroek has contributed to landmark cardiovascular outcomes research.